Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Pharmacyte Biotech Inc (PMCB)

Pharmacyte Biotech Inc (PMCB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment Business Wire - Tue Nov 25, 2025

PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ: FEMY), further validating the Company’s...

PMCB : 0.8815 (-4.28%)
FEMY : 0.5943 (+0.64%)
PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications Business Wire - Tue Sep 2, 2025

TNF new strategic partner LightSolver named a 2025 World Economic Forum Technology Pioneer and recognized in Gartner’s 2025 Hype Cycle for Data Center Infrastructure...

PMCB : 0.8815 (-4.28%)
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing Business Wire - Wed Aug 20, 2025

PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the closing of its previously announced $7 million financing. As of April 30, 2025, PharmaCyte had...

PMCB : 0.8815 (-4.28%)
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors Business Wire - Mon Aug 18, 2025

PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”) announced today that it has entered into a securities purchase agreement for a $7.0 million financing with existing investors...

PMCB : 0.8815 (-4.28%)
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan Business Wire - Thu Feb 2, 2023

PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a-Box ® for potential...

PMCB : 0.8815 (-4.28%)
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital Business Wire - Mon Aug 15, 2022

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology,...

PMCB : 0.8815 (-4.28%)
PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation Business Wire - Thu Jul 28, 2022

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology,...

PMCB : 0.8815 (-4.28%)
PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study Business Wire - Thu Jul 21, 2022

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology,...

PMCB : 0.8815 (-4.28%)
PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study Business Wire - Tue Jul 19, 2022

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology,...

PMCB : 0.8815 (-4.28%)
PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022 Business Wire - Mon Jul 11, 2022

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology,...

PMCB : 0.8815 (-4.28%)

Barchart Exclusives

As Meta Delays New Ray-Ban Display Glasses, Should You Buy, Sell, or Hold META Stock? Barchart - Sat Jan 10, 2:19PM CST
Meta’s pause on the global rollout of its Ray-Ban Display smart glasses leaves investors to weigh whether META is a buy, sell, or hold at this pivotal moment. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot